@article{Rizzo_2010,<br/><span class="tab"></span> title={Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?},<br/><span class="tab"></span> volume={36},<br/><span class="tab"></span> ISSN={0305-7372},<br/><span class="tab"></span> url={http://dx.doi.org/10.1016/s0305-7372(10)70021-9},<br/><span class="tab"></span> DOI={10.1016/s0305-7372(10)70021-9},<br/><span class="tab"></span> journal={Cancer Treatment Reviews},<br/><span class="tab"></span> publisher={Elsevier BV},<br/><span class="tab"></span> author={Rizzo,<br/><span class="tab"></span> Sergio and Bronte,<br/><span class="tab"></span> Giuseppe and Fanale,<br/><span class="tab"></span> Daniele and Corsini,<br/><span class="tab"></span> Lidia and Silvestris,<br/><span class="tab"></span> Nicola and Santini,<br/><span class="tab"></span> Daniele and Gulotta,<br/><span class="tab"></span> Gaspare and Bazan,<br/><span class="tab"></span> Viviana and Gebbia,<br/><span class="tab"></span> Nicola and Fulfaro,<br/><span class="tab"></span> Fabio and Russo,<br/><span class="tab"></span> Antonio},<br/><span class="tab"></span> year={2010},<br/><span class="tab"></span> month=nov,<br/><span class="tab"></span> pages={S56–S61} }